Resistance to epidermal growth factor receptor tyrosine kinase inhibitors remains one of the most pressing clinical challenges in the management of EGFR-mutated non–small-cell lung cancer. While third-generation TKIs such as osimertinib have markedly improved first-line outcomes, virtually all patients eventually develop disease progression, leaving clinicians with limited second-line options. The Phase III OptiTROP-Lung04 trial, published in the New England Journal of Medicine, now provides compelling evidence that sacituzumab tirumotecan — a novel TROP2-directed antibody-drug conjugate — can meaningfully improve both progression-free and overall survival in this difficult-to-treat population.
Trial Design and Patient Population
OptiTROP-Lung04 was a randomized, open-label, multicenter Phase III study that enrolled 376 patients with EGFR-mutated locally advanced or metastatic nonsquamous NSCLC who had progressed following EGFR-TKI therapy. Eligible patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and documented disease progression after treatment with a third-generation EGFR-TKI, or after first- or second-generation TKIs in patients without the T790M resistance mutation.
The study population was broadly representative: the median age was 59.5 years, 39.6% were male, approximately 79.3% had an ECOG performance status of 1, and nearly all patients (94.7%) had previously received a third-generation EGFR-directed TKI. Patients were randomly assigned in a 1:1 ratio to one of two treatment arms.
Treatment Arms and Rationale
Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate that targets trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein that is broadly expressed across epithelial tumors including NSCLC. Unlike conventional chemotherapy, sac-TMT delivers a potent topoisomerase I inhibitor payload directly to tumor cells via TROP2 binding, offering a precision mechanism with potentially less systemic toxicity.
| Parameter | Arm A: Sac-TMT | Arm B: Chemotherapy |
|---|---|---|
| Regimen | Sacituzumab tirumotecan 5 mg/kg IV | Pemetrexed 500 mg/m² + carboplatin AUC 5 or cisplatin 75 mg/m² |
| Schedule | Every 2 weeks | Every 3 weeks × 4 cycles, then pemetrexed maintenance |
| Patients Randomized | 188 | 188 |
| Maintenance | Continued until progression or unacceptable toxicity | Pemetrexed 500 mg/m² every 3 weeks |
The comparator arm reflected the current standard of care for this patient population — platinum-based doublet chemotherapy with pemetrexed, followed by pemetrexed maintenance — making this a rigorously designed head-to-head comparison.
Primary Efficacy Endpoints
After a median follow-up of 18.9 months, the trial met both of its co-primary endpoints with impressive statistical significance.
“The application of third-generation EGFR-TKIs has significantly improved the overall prognosis for patients with advanced EGFR-mutant NSCLC, but drug resistance is almost inevitable. The OptiTROP-Lung04 study confirms sac-TMT as the first treatment option as a monotherapy to deliver clear dual benefits in both PFS and OS following EGFR-TKI progression.”
— Prof. Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University
The magnitude of PFS benefit (HR 0.49) is among the most robust seen in the post–EGFR-TKI setting, nearly doubling median progression-free survival compared to platinum-based chemotherapy. The OS benefit (HR 0.60) is equally striking, confirming that the PFS gains translate into a meaningful survival advantage — a critical benchmark for practice-changing evidence.
OS benefits were observed across all prespecified subgroups, reinforcing the consistency and generalizability of these findings.
Safety Profile
The safety profile of sac-TMT compared favorably with platinum-based chemotherapy. Grade 3 or higher treatment-related adverse events occurred in 49.5% of sac-TMT patients versus 52.2% of chemotherapy patients, suggesting similar or slightly lower high-grade toxicity. Critically, serious TRAEs were substantially lower with sac-TMT (9.0%) compared to chemotherapy (17.6%).
The most common treatment-related adverse events in both arms were hematologic toxicities, including neutropenia and leukopenia. Sac-TMT was associated with a higher incidence of stomatitis, though most cases were mild (grade 1–2), with grade 3 events occurring in only 4.8% of patients (no grade 4 or 5 stomatitis). Ocular surface toxicity was observed in 9.6% of sac-TMT patients, all grade 1–2. Notably, no cases of interstitial lung disease or pneumonitis were reported in the sac-TMT arm — a safety concern with some other ADCs — and only one grade 2 infusion-related reaction was noted.
| Safety Parameter | Sac-TMT (n=188) | Chemotherapy (n=188) |
|---|---|---|
| Grade ≥3 TRAEs | 49.5% | 52.2% |
| Serious TRAEs | 9.0% | 17.6% |
| Stomatitis (any grade) | Elevated (mostly grade 1–2) | Lower incidence |
| Grade ≥3 Stomatitis | 4.8% | — |
| Ocular Surface Toxicity | 9.6% (all grade 1–2) | — |
| ILD/Pneumonitis | 0% | — |
| Infusion Reactions | 1 case (grade 2) | — |
Clinical Interpretation and Practice Implications
The OptiTROP-Lung04 results represent a paradigm shift in the treatment of EGFR-TKI–resistant NSCLC. Until now, platinum-based chemotherapy — either alone or combined with immunotherapy — has served as the default second-line regimen following TKI failure. While these approaches offer modest benefit, outcomes have remained unsatisfactory, with median PFS typically ranging from 4 to 5 months.
Sacituzumab tirumotecan is the first monotherapy to demonstrate dual improvements in both PFS and OS in this setting. As Professor Shengxiang Ren of Shanghai Pulmonary Hospital noted, while third-generation EGFR-TKIs have improved outcomes, drug resistance is almost inevitable, and the OptiTROP-Lung04 study establishes sac-TMT as a differentiated treatment option that avoids the toxicity burden of combination chemotherapy regimens.
Based on these results, the National Medical Products Administration (NMPA) in China has already approved sac-TMT for the treatment of adult patients with EGFR mutation-positive locally advanced or metastatic nonsquamous NSCLC who have progressed after EGFR-TKI therapy. Regulatory submissions in other regions are anticipated.
Outstanding Questions and Future Directions
Several questions remain that future research will need to address. First, the optimal sequencing of sac-TMT relative to other emerging post-TKI options — including combinations of chemotherapy with immunotherapy or other ADCs — requires further investigation. Second, while the OptiTROP-Lung04 population was predominantly East Asian, confirmation of benefit across broader ethnic groups will be important for global applicability.
The OptiTROP-Lung05 trial, which evaluates sac-TMT in combination with pembrolizumab as first-line therapy for PD-L1–positive NSCLC, has already met its primary endpoint, suggesting that the therapeutic potential of this ADC may extend well beyond the post-TKI resistance setting. Additionally, biomarker studies to identify patients most likely to benefit — including TROP2 expression levels and mechanisms of EGFR-TKI resistance — could further refine patient selection.
Conclusion
The Phase III OptiTROP-Lung04 trial establishes sacituzumab tirumotecan as a practice-changing treatment option for patients with EGFR-mutated NSCLC following EGFR-TKI failure. With a 51% reduction in the risk of progression, a 40% reduction in the risk of death, and a manageable safety profile, sac-TMT offers meaningful improvement over platinum-based chemotherapy — the longstanding standard of care. These results mark a pivotal moment in the evolving treatment landscape for EGFR-driven lung cancer and underscore the growing role of antibody-drug conjugates in precision oncology.